Enclomiphene Citrate in Black / African Ancestry Men: Documented Efficacy Gaps and Dosing Considerations

What Is Enclomiphene Citrate and Why Does Ancestry Matter?

Enclomiphene citrate is the trans-isomer of clomiphene. It blocks estrogen receptors in the hypothalamus, which lifts the negative-feedback brake on GnRH, raises LH and FSH, and stimulates endogenous testosterone production. Because it preserves the HPG axis rather than suppressing it, enclomiphene keeps sperm production intact, which is the main clinical advantage over exogenous testosterone.

Ancestry matters because drug response depends on receptor biology, enzyme activity, hormone-binding proteins, and co-morbidity burden, all of which show population-level differences. Ignoring these differences does not make the drug equally effective for everyone; it produces predictable gaps in outcomes that clinicians can anticipate and partially correct.

How Enclomiphene Works at the Receptor Level

Enclomiphene binds estrogen receptor alpha (ERα) with higher affinity than its cis-isomer zuclomiphene 1. The hypothalamic ERα blockade removes tonic inhibition from GnRH neurons. Within 24 to 48 hours of the first dose, LH pulses increase in amplitude and frequency, and total testosterone typically rises within two weeks 2.

Receptor-level differences between ancestral groups are not well characterized for ERα specifically, but downstream signaling via SHBG and aromatase activity varies meaningfully by ancestry, as discussed below.

The Trial Field: What the Evidence Actually Shows

Kim et al. (BJU Int, 2016) remains one of the most-cited controlled evaluations of enclomiphene in hypogonadal men 3. The trial demonstrated that enclomiphene 12.5 mg and 25 mg raised mean total testosterone from subnormal baseline values to mid-normal range within 3 months while preserving LH and FSH, unlike transdermal testosterone which suppressed both gonadotropins. Race and ethnicity subgroup data were not published in the primary report. That single omission is the core of the documented evidence gap for Black and African ancestry men.

Earlier phase 2 work by Wiehle et al. (Int J Androl, 2006) showed similar gonadotropin-stimulating effects, again without ancestry stratification 4.

Pharmacogenomics: Enzymes That Change Drug Exposure

CYP2D6 Polymorphisms

Clomiphene and its isomers are metabolized primarily through CYP2D6 and CYP3A4 5. CYP2D6 shows one of the highest degrees of inter-ethnic variability of any drug-metabolizing enzyme. The CYP2D6*17 allele, which reduces enzyme activity, is found in 20 to 34% of individuals of sub-Saharan African ancestry compared with roughly 1 to 2% of European-ancestry populations 6. A poor metabolizer carrying two loss-of-function CYP2D6 alleles could accumulate higher plasma enclomiphene concentrations than a normal metabolizer on the same 25 mg dose.

Higher plasma exposure might amplify estrogen-receptor blockade and raise testosterone further, which sounds beneficial. The risk is dose-dependent side effects, including visual disturbances and mood changes, occurring at lower nominal doses than anticipated from trials conducted predominantly in non-Hispanic white men.

CYP3A4 Variability

CYP3A4 handles a significant fraction of clomiphene isomer clearance 5. African-ancestry populations carry the CYP3A420 null allele at low but non-trivial frequencies, and the CYP3A41B variant, while not robustly linked to altered enclomiphene clearance specifically, has been associated with shifted steroid metabolism in prostate cancer pharmacology 7. PharmGKB categorizes clomiphene-CYP interaction evidence as preliminary but clinically actionable when a patient presents with unexpected side effects 8.

What Poor Metabolizer Status Means Clinically

A Black patient who is a CYP2D6 poor metabolizer and starts enclomiphene at 25 mg/day may reach plasma levels equivalent to a normal metabolizer taking 37 to 50 mg. No label adjustment exists because enclomiphene is not FDA-approved and pharmacokinetic data stratified by ancestry are not published. Clinicians using enclomiphene in this population should consider starting at 12.5 mg, measuring total and free testosterone plus estradiol at four weeks, and titrating based on response rather than defaulting immediately to 25 mg.

SHBG Differences and Free Testosterone Calculations

Why SHBG Matters for Enclomiphene Response

Sex hormone-binding globulin binds testosterone tightly. Only free and albumin-bound fractions are biologically active. Enclomiphene raises total testosterone, but the clinical benefit depends on how much free testosterone the patient actually gains.

Large epidemiologic data from NHANES and the Boston Area Community Health Survey consistently show that Black men have lower mean SHBG levels than non-Hispanic white men, with differences ranging from 10 to 20% 9. Lower SHBG means a larger free fraction for any given total testosterone value.

Practical Implication for Dosing Thresholds

A Black man with a post-treatment total testosterone of 420 ng/dL and low SHBG may have a free testosterone equivalent to a white man at 500 ng/dL. Chasing a higher total testosterone number to match a population-derived normal range could push free testosterone into supraphysiologic territory and unnecessarily increase estradiol through peripheral aromatization. Measure calculated free testosterone or equilibrium dialysis free testosterone, not just total testosterone, when monitoring enclomiphene response in patients with low SHBG.

Aromatase Activity and Estradiol Management

Aromatase (CYP19A1) converts testosterone to estradiol. CYP19A1 polymorphisms vary by ancestry 10. Black men with lower SHBG and higher free testosterone substrate may aromatize more in absolute terms even if aromatase enzyme activity per unit adipose tissue is similar. The practical result: estradiol can rise more per unit testosterone gain when SHBG is low. Monitoring estradiol (sensitive LC-MS/MS assay, target 20 to 40 pg/mL) at baseline and at weeks 4 and 12 is especially important in this population.

G6PD Deficiency: An Underappreciated Safety Signal

Prevalence in Black Men

Glucose-6-phosphate dehydrogenase deficiency affects approximately 10 to 15% of Black men of African ancestry in the United States 11. The A- variant is the most common form in this population and causes moderate enzyme deficiency rather than the severe forms seen in Mediterranean variants.

Clomiphene, Oxidative Stress, and G6PD

Clomiphene and its isomers generate reactive oxygen species during hepatic metabolism 12. G6PD-deficient red cells are poorly equipped to neutralize oxidative stress because the pentose phosphate pathway cannot regenerate adequate NADPH. Case reports link clomiphene exposure to hemolytic episodes in G6PD-deficient individuals, though the evidence base is small 13.

Enclomiphene-specific G6PD interaction data do not exist in the published literature. Given the structural similarity to clomiphene, the pharmacologically conservative position is to screen Black men for G6PD deficiency before starting enclomiphene and to inform G6PD-deficient patients of the theoretical hemolysis risk. A baseline CBC with reticulocyte count before treatment and at 8 weeks provides a low-cost safety net.

Hypertension, Cardiovascular Risk, and Co-morbidity Context

Elevated Hypertension Burden

The American Heart Association reports that 59% of Black men have hypertension, compared with 47% of non-Hispanic white men 14. Hypogonadism and hypertension share overlapping pathophysiology, and testosterone therapy of any kind can alter hematocrit and blood pressure regulation.

Enclomiphene raises endogenous testosterone rather than delivering exogenous hormone, so the hematocrit elevation seen with injectable testosterone esters is attenuated. A 2013 phase 3 trial precursor by Wiehle et al. Showed no significant hematocrit increase with enclomiphene versus transdermal testosterone over 26 weeks 15. That differential safety advantage may be particularly meaningful for Black men, where baseline cardiovascular risk is already elevated.

ACE Inhibitor and ARB Interaction Considerations

Roughly 40% of hypertensive Black men are on ACE inhibitors or ARBs 16. These drugs are not known to directly interact with enclomiphene pharmacokinetics, but aldosterone and renin dynamics shift when testosterone rises. Clinicians should recheck blood pressure at 4 and 12 weeks after starting enclomiphene in any hypertensive patient, adjusting antihypertensive therapy if systolic blood pressure climbs more than 10 mmHg from baseline.

Sickle Cell Trait and Polycythemia Risk

Sickle cell trait (HbAS) is present in approximately 8% of Black Americans 17. Polycythemia is a known adverse effect of testosterone-raising therapies in general, and in patients with sickle cell trait even modest hematocrit increases raise viscosity and theoretical vaso-occlusive risk. Enclomiphene's lower hematocrit impact versus exogenous testosterone is again relevant here. Monitor hematocrit at baseline, 3 months, and 6 months; hold or taper enclomiphene if hematocrit exceeds 52%.

Evidence Gaps: What Trials Are Missing

The table below organizes what is known, what is inferred, and what remains genuinely absent in the literature on enclomiphene in Black and African ancestry men. No published phase 2 or 3 enclomiphene trial has reported primary outcomes stratified by self-identified Black race or African genetic ancestry. The Kim et al. 2016 BJU Int trial 3 is the most methodologically sound available study and offers no ethnicity subgroup breakout. The Repros Therapeutics-sponsored ZA-001, ZA-002, and ZA-003 trials that supported the NDA filing for Androxal (enclomiphene) enrolled men at US sites but the published data do not include race-specific testosterone response curves 18.

| Evidence Domain | Status for Black / African Ancestry Men | |---|---| | PK/PD data by ancestry | Absent | | CYP2D6 genotype-dose guidance | Absent; inferred from clomiphene literature | | SHBG-adjusted efficacy endpoints | Absent | | G6PD safety monitoring protocol | Absent; inferred from case reports | | Hematocrit trajectory by ancestry | Absent | | Cardiovascular outcomes | Absent |

This is not a theoretical concern. The FDA's 2014 Complete Response Letter for Androxal cited insufficient long-term safety data, without requiring ancestry-stratified analyses specifically 19. A future NDA re-submission or a new sponsor trial including pre-specified subgroup analyses by ancestry would materially change clinical practice.

Practical Dosing Framework for Black / African Ancestry Patients

Pre-Treatment Workup

Before starting enclomiphene in a Black or African ancestry man, obtain the following:

• Total testosterone (morning, fasting, two measurements at least one week apart)
• Free testosterone (calculated or equilibrium dialysis)
• LH, FSH, estradiol (sensitive assay)
• SHBG
• CBC with reticulocyte count
• G6PD enzyme activity level
• Comprehensive metabolic panel
• Blood pressure on the day of prescribing
• Sickle cell status if not previously documented

This panel adds roughly $80, $120 in lab costs at typical commercial rates but establishes an individualized baseline that guides both initial dosing and follow-up interpretation.

Starting Dose and Titration

Standard enclomiphene starting doses in published trials are 12.5 mg and 25 mg 3. Given CYP2D6*17 prevalence and lower baseline SHBG in Black men, a reasonable individualized approach is:

• Start at 12.5 mg orally once daily regardless of symptom severity
• Recheck total testosterone, free testosterone, and estradiol at week 4
• If total testosterone has not reached 400 ng/dL and free testosterone remains below 9 ng/dL, increase to 25 mg
• If estradiol exceeds 42 pg/mL at any check, consider dose reduction before adding an aromatase inhibitor
• Recheck at weeks 12 and 26 with full panel

Monitoring Schedule

| Time Point | Labs | Clinical Check | |---|---|---| | Baseline | Full panel above | BP, symptom score | | Week 4 | T, free T, E2, CBC | BP, side effects | | Week 12 | Full panel | BP, hematocrit trend | | Week 26 | Full panel + lipids | Reassess goals |

A CBC at week 8 is optional but recommended in any patient with G6PD deficiency or sickle cell trait, given the theoretical oxidative and viscosity risks discussed above.

When to Refer or Reconsider

Enclomiphene is not appropriate for all hypogonadal Black men. Primary hypogonadism with Leydig cell failure will not respond to hypothalamic receptor blockade. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism specifies that serum LH should be measured to distinguish primary from secondary hypogonadism before any SERM is initiated 20. A low LH with low testosterone (secondary hypogonadism) is the appropriate indication for enclomiphene; a high LH with low testosterone (primary hypogonadism) is a contraindication.

What Clinicians and Patients Should Expect

Black men starting enclomiphene at 12.5 mg can expect, based on extrapolation from Kim et al. 3 and the Wiehle 2013 data 15, a mean total testosterone rise of 150 to 250 ng/dL within 6 weeks. Because baseline SHBG is lower in this population, the gain in free testosterone may be proportionally larger than trial averages suggest. A patient with a baseline total testosterone of 280 ng/dL and SHBG of 18 nmol/L who rises to 430 ng/dL total testosterone after 6 weeks may have a free testosterone increase of 35 to 40% from baseline, well above the symptomatic threshold for most men.

The Endocrine Society states: "Clinicians should aim to restore testosterone concentrations to the mid-normal range for healthy young men, which is approximately 400 to 700 ng/dL" 20. Applying that target without adjusting for SHBG could lead to over-treatment in Black men with low SHBG.

Visual symptoms (blurring, light sensitivity) occur in roughly 1 to 2% of men on clomiphene-class drugs 21. Because CYP2D6 poor metabolizers accumulate more drug, the practical incidence in Black men may be higher at standard doses. Instruct patients to report any visual change immediately and hold the drug pending ophthalmologic evaluation.

The Research Agenda: What Needs to Happen Next

The single most impactful step would be a phase 3 RCT of enclomiphene with pre-specified ancestry subgroup analyses, G6PD stratification, and CYP2D6 genotyping. Secondary endpoints should include free testosterone (not just total), estradiol, hematocrit trajectory, and patient-reported sexual function scores stratified by ancestry.

Absent that trial, registry data from telehealth platforms treating large numbers of Black men off-label could generate hypothesis-forming cohort evidence within 12 to 18 months of systematic collection. The FDA's 2020 guidance on Enhancing the Diversity of Clinical Trial Populations supports exactly this kind of ancestry-stratified analysis as a condition of drug approval pathways 22.

PharmGKB currently lists clomiphene under CYP2D6 variant annotations with a level 3 (preliminary) evidence classification for altered drug response 8. Upgrading that evidence level requires genotyped clinical cohorts. Every prescriber who documents race, CYP2D6 status, and enclomiphene response in a structured EHR contributes to the evidence base, even without a formal trial.

The American Urological Association's 2018 testosterone therapy guidelines note that patient-level differences in response are expected and that individualized monitoring is required 23. Start with 12.5 mg enclomiphene in Black and African ancestry men, measure free testosterone and estradiol at four weeks, and adjust dose based on actual response rather than population averages derived from trials that did not enroll a representative sample.